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• Bardoxolone methyl (BARD) activates Nrf2 and suppresses NF-kB − Nrf2 activation is reno-protective in kidney disease models 1,2 − BARD increases expression of antioxidant genes to reduce inflammation and pro-proliferative drive 3, 4 • BARD targets inflammatory pathways that contribute to GFR loss in chronic kidney diseases [5] [6] [7] • BARD significantly increases eGFR, inulin clearance, creatinine clearance, and other markers of kidney function across 7 clinical trials in patient with CKD that enrolled over 2,600 patients with CKD 8-11 • In Phase 2 BEAM and Phase 3 BEACON studies 10, 11 − BARD increased eGFR (p < 0.0001) − Durable eGFR change through 1 year and retained benefit four weeks after drug cessation, suggesting disease-modifying activity − Fewer renal SAEs and ESRD events in BARD vs placebo patients • BEACON study was terminated early due to increased risk for fluid overload hospitalizations within first four weeks. The average age of patients in the study was 68.5±9.6 • Post-hoc analyses identified baseline BNP > 200 pg/ml and prior history of heart failure were risk factors for fluid overload in BEACON 12 and these were used to exclude at-risk patients in subsequent studies • BARD has potential to prevent kidney function decline and delay or prevent ESRD in patients with Alport syndrome • Reata has initiated a pivotal Phase 2/3 study (CARDINAL) in patients with Alport syndrome 
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